These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 7844604)
1. High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer. Smith IE; Walsh G; Jones A; Prendiville J; Johnston S; Gusterson B; Ramage F; Robertshaw H; Sacks N; Ebbs S J Clin Oncol; 1995 Feb; 13(2):424-9. PubMed ID: 7844604 [TBL] [Abstract][Full Text] [Related]
2. Phase II study of continuous infusion fluorouracil with epirubicin and cisplatin in patients with metastatic and locally advanced breast cancer: an active new regimen. Jones AL; Smith IE; O'Brien ME; Talbot D; Walsh G; Ramage F; Robertshaw H; Ashley S J Clin Oncol; 1994 Jun; 12(6):1259-65. PubMed ID: 8201387 [TBL] [Abstract][Full Text] [Related]
3. Phase II study of continuous infusional 5-fluorouracil with epirubicin and carboplatin (instead of cisplatin) in patients with metastatic/locally advanced breast cancer (infusional ECarboF): a very active and well-tolerated outpatient regimen. Bonnefoi H; Smith IE; O'Brien ME; Seymour MT; Powles TJ; Allum WH; Ebbs S; Baum M Br J Cancer; 1996 Feb; 73(3):391-6. PubMed ID: 8562348 [TBL] [Abstract][Full Text] [Related]
4. Primary medical (neo-adjuvant) chemotherapy for operable breast cancer. Smith IE; Jones AL; O'Brien ME; McKinna JA; Sacks N; Baum M Eur J Cancer; 1993; 29A(12):1796-9. PubMed ID: 8398318 [TBL] [Abstract][Full Text] [Related]
5. A novel continuous infusional 5-fluorouracil-based chemotherapy regimen compared with conventional chemotherapy in the neo-adjuvant treatment of early breast cancer: 5 year results of the TOPIC trial. Smith IE; A'Hern RP; Coombes GA; Howell A; Ebbs SR; Hickish TF; O'Brien ME; Mansi JL; Wilson CB; Robinson AC; Murray PA; Price CG; Perren TJ; Laing RW; Bliss JM; Ann Oncol; 2004 May; 15(5):751-8. PubMed ID: 15111342 [TBL] [Abstract][Full Text] [Related]
6. Randomized phase II trial of infusional fluorouracil, epirubicin, and cyclophosphamide versus infusional fluorouracil, epirubicin, and cisplatin in patients with advanced breast cancer. Eisen T; Smith IE; Johnston S; Ellis PA; Prendiville J; Seymour MT; Walsh G; Ashley S J Clin Oncol; 1998 Apr; 16(4):1350-7. PubMed ID: 9552036 [TBL] [Abstract][Full Text] [Related]
7. Epirubicin, cisplatin, and prolonged or brief infusional 5-fluorouracil in the treatment of carcinoma of unknown primary site. Karapetis CS; Yip D; Virik K; Strickland A; Ryder K; Cowling M; Harper PG Med Oncol; 2001; 18(1):23-32. PubMed ID: 11778966 [TBL] [Abstract][Full Text] [Related]
8. Infusional fluorouracil, epirubicin, and cisplatin followed by weekly paclitaxel plus bevacizumab in locally advanced breast cancer with unfavorable prognostic features. Balduzzi A; Montagna E; Bagnardi V; Torrisi R; Bertolini F; Mancuso P; Scarano E; Viale G; Veronesi P; Cardillo A; Orlando L; Goldhirsch A; Colleoni M Anticancer Drugs; 2009 Mar; 20(3):197-203. PubMed ID: 19182679 [TBL] [Abstract][Full Text] [Related]
9. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer. Klaassen U; Wilke H; Seeber S Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897 [TBL] [Abstract][Full Text] [Related]
10. Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial. Del Mastro L; De Placido S; Bruzzi P; De Laurentiis M; Boni C; Cavazzini G; Durando A; Turletti A; Nisticò C; Valle E; Garrone O; Puglisi F; Montemurro F; Barni S; Ardizzoni A; Gamucci T; Colantuoni G; Giuliano M; Gravina A; Papaldo P; Bighin C; Bisagni G; Forestieri V; Cognetti F; Lancet; 2015 May; 385(9980):1863-72. PubMed ID: 25740286 [TBL] [Abstract][Full Text] [Related]
11. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer. Iwata H; Sato N; Masuda N; Nakamura S; Yamamoto N; Kuroi K; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Toi M Jpn J Clin Oncol; 2011 Jul; 41(7):867-75. PubMed ID: 21719750 [TBL] [Abstract][Full Text] [Related]
12. Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collaborative Cancer Group. Coombes RC; Bliss JM; Wils J; Morvan F; Espié M; Amadori D; Gambrosier P; Richards M; Aapro M; Villar-Grimalt A; McArdle C; Pérez-López FR; Vassilopoulos P; Ferreira EP; Chilvers CE; Coombes G; Woods EM; Marty M J Clin Oncol; 1996 Jan; 14(1):35-45. PubMed ID: 8558217 [TBL] [Abstract][Full Text] [Related]
13. Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for advanced gastric carcinoma. Cho EK; Lee WK; Lim DY; Bang SM; Park DK; Park YH; Kwon OS; Choi DJ; Shin DB; Lee JH; Lee TH J Korean Med Sci; 2002 Jun; 17(3):348-52. PubMed ID: 12068138 [TBL] [Abstract][Full Text] [Related]
14. [Early stage breast cancer: is exclusive radiotherapy an option for early breast cancers with complete clinical response after neoadjuvant chemotherapy?]. Daveau C; Savignoni A; Abrous-Anane S; Pierga JY; Reyal F; Gautier C; Kirova YM; Dendale R; Campana F; Fourquet A; Bollet MA Cancer Radiother; 2011 Apr; 15(2):106-14. PubMed ID: 21084207 [TBL] [Abstract][Full Text] [Related]
15. A phase II study of epirubicin, cisplatin and capecitabine as neoadjuvant chemotherapy in locally advanced or inflammatory breast cancer. Villman K; Ohd JF; Lidbrink E; Malmberg L; Lindh B; Blomqvist C; Nordgren H; Bergh J; Bergström D; Ahlgren J Eur J Cancer; 2007 May; 43(7):1153-60. PubMed ID: 17398088 [TBL] [Abstract][Full Text] [Related]
16. Phase II trial combining paclitaxel with 24-hour infusion cisplatin for chemotherapy-naïve patients with locally advanced or metastatic breast carcinoma. Hsu C; Huang CS; Chao TY; Lu YS; Bu CF; Chen MM; Chang KJ; Cheng AL Cancer; 2002 Nov; 95(10):2044-50. PubMed ID: 12412156 [TBL] [Abstract][Full Text] [Related]
17. Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel. Torrisi R; Balduzzi A; Ghisini R; Rocca A; Bottiglieri L; Giovanardi F; Veronesi P; Luini A; Orlando L; Viale G; Goldhirsch A; Colleoni M Cancer Chemother Pharmacol; 2008 Sep; 62(4):667-72. PubMed ID: 18064460 [TBL] [Abstract][Full Text] [Related]
18. Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for esophagogastric adenocarcinoma: response, toxicity, quality of life, and survival. Bamias A; Hill ME; Cunningham D; Norman AR; Ahmed FY; Webb A; Watson M; Hill AS; Nicolson MC; O'Brien ME; Evans TC; Nicolson V Cancer; 1996 May; 77(10):1978-85. PubMed ID: 8640659 [TBL] [Abstract][Full Text] [Related]
19. High pathologic complete response in HER 2-positive locally advanced breast cancer after primary systemic chemotherapy with weekly docetaxel and epirubicin. Chen SC; Chang HK; Lin YC; Hsueh S; Cheung YC; Leung WM; Tsai CS; Lo YF; Tsai HP; Shen SC; Chen MF Jpn J Clin Oncol; 2008 Feb; 38(2):99-105. PubMed ID: 18270380 [TBL] [Abstract][Full Text] [Related]
20. Phase II trial of epirubicin, cisplatin, oral uracil and tegafur, and leucovorin in patients with advanced gastric carcinoma. Jeen YT; Yoon SY; Shin SW; Kim BS; Mok YJ; Kim CS; Hyun JH; Kim JS; Kim YH Cancer; 2001 Jun; 91(12):2288-93. PubMed ID: 11413517 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]